Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.

CA: a cancer journal for clinicians - 1 Jan 2025

Sabzevari Ariana, Ung Johnson, Craig Jeffrey W, Jayappa Kallesh D, Pal Ipsita, Feith David J, Loughran Thomas P, O'Connor Owen A

Abstract excerpt

The peripheral T-cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential. Many lines of data have established that the PTCL exhibit marked sensitivity to other epigenetically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Histone Deacetylase Inhibitors

Share to Lymphoma, T-Cell, Peripheral

Share to Molecular Targeted Therapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 40232267
DOI: 10.3322/caac.70001
PMCID: PMC12223354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.PMID 40232267Read ↗

Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical RealitySemantic proximity Read ↗

Genetic Landscape and Classification of Peripheral T Cell Lymphomas.Semantic proximity Read ↗

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.Semantic proximity Read ↗

New insights in the pathogenesis of T-cell lymphomasSemantic proximity Read ↗

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.Semantic proximity Read ↗

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.Semantic proximity Read ↗

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read ↗

The new biology of PTCL‐NOS and AITL: current status and future clinical impactSemantic proximity Read ↗

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Semantic proximity Read ↗

Peripheral T cell lymphomas: from the bench to the clinic.Semantic proximity Read ↗

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysSemantic proximity Read ↗

Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.